PT - JOURNAL ARTICLE AU - Ishikawa, Koji AU - Tani, Soji AU - Toyone, Tomoaki AU - Tsuchiya, Koki AU - Towatari, Tomoko AU - Oshita, Yusuke AU - Yamamura, Ryo AU - Nagai, Takashi AU - Shirahata, Toshiyuki AU - Inagaki, Katsunori AU - Kudo, Yoshifumi TI - The potential effect of romosozumab on perioperative management for instrumentation surgery AID - 10.1101/2023.11.09.23298298 DP - 2023 Jan 01 TA - medRxiv PG - 2023.11.09.23298298 4099 - http://medrxiv.org/content/early/2023/11/11/2023.11.09.23298298.short 4100 - http://medrxiv.org/content/early/2023/11/11/2023.11.09.23298298.full AB - Background Age-related changes in bone health increase the risk for complications in elderly patients undergoing orthopedic surgery. Osteoporosis is a key therapeutic target that needs to be addressed to ensure successful instrumentation surgery. The effectiveness of pharmacological interventions in orthopedic surgery, particularly the new drug romosozumab, is still unknown. We aim to evaluate the effect of 3-month romosozumab treatment on biomechanical parameters related to spinal instrumentation surgery, using the Quantitative Computed Tomography (QCT)-based Finite Element Method (FEM).Methods This open-labeled, prospective study included 81 patients aged 60 to 90 years, who met the osteoporosis criteria and were scheduled for either romosozumab or eldecalcitol treatment. Patients were assessed using blood samples, dual-energy absorptiometry (DXA), and QCT. Biomechanical parameters were evaluated using FEM at baseline and 3 months post-treatment. The primary endpoints were biomechanical parameters at 3 months, while secondary endpoints included changes in regional volumetric bone mineral density around the pedicle (P-vBMD) and vertebral body (V-vBMD).Results Romosozumab treatment led to significant gains in P-vBMD, and V-vBMD compared to eldecalcitol at 3 months. Notably, the romosozumab group showed greater improvements in all biomechanical parameters estimated by FEM at 3 months compared to the eldecalcitol group.Conclusion Romosozumab significantly increased the regional vBMD as well as biomechanical parameters, potentially offering clinical benefits in reducing post-operative complications in patients with osteoporosis undergoing orthopedic instrumentation surgery. This study highlights the novel advantages of romosozumab treatment and advocates further research on its effectiveness in perioperative management.Competing Interest StatementK.I. and T.N. received a speaking fee from Amgen.Funding StatementThis work was supported in part by a grant for the Grants-in-Aid for Scientific Research (C) to K. I. (22K12896), Scientific Research (C) to T.T. (16K10838), Y. K. (22K12896), and Fostering Joint International Research (A) (22KK0265) to K. I. from the Japan Society for the Promotion of Science (JSPS) KAKENHI.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has complied with all the relevant national regulations, institutional policies, and the tenets of the Helsinki Declaration, and has been approved by the authors' institutional review board (Yamanashi Red Cross Hospital: 30-17).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.